Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses

NCT07617090 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2025-09-29
Last updated
2026-06-01

Condition(s) studied

Presbyopia

Investigational drug(s) / intervention(s)

OPAL PC assesmentOPAL Office assessmentPAL assesment

OPAL PC assesment: Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

OPAL Office assessment: Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

PAL assesment: Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

Study summary

This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax Zoom 1.5 FWD 4 m and Vimax PC 1.5 FWD 4 m lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances.

Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both study lenses under standardized conditions. Subjects will be instructed to maintain a fixed head position while identifying optotypes located at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. Both lenses will be tested in random order under masked conditions so that neither participants nor investigators know which lens design is being evaluated during each phase.

At least 23 presbyopic participants are expected to be enrolled. The study procedures are non-invasive and are anticipated to be completed in a single one-hour visit, although additional sessions may be scheduled if necessary. No significant risks are expected beyond possible transient visual fatigue associated with the duration of testing.

The primary objective is to determine which occupational progressive lens design provides a greater spatial volume of clear vision and wider horizontal and vertical visual fields at different intermediate and near distances. The findings may contribute to improving personalized recommendations of occupational lenses according to patients' visual demands and working distances.

Eligibility

Sex
ALL
Min age
52 Years
Max age
67 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D. * Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses. * Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye Exclusion Criteria: * Astigmatism greater than ±1.00 D. * Patients wearing progressive contact lenses. * Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses. * Anisometropia greater than 2.50 D. * Decimal distance visual acuity \< 0.8 (UCVA or BCVA) with monofocal contact lenses. * Patients without normal ocular motility or with partial dysfunction of one or more ex-traocular muscles, or with restricted visual fields or scotomas. * Visual suppression in one eye between 4 m and 25 cm. * Strabismus or nystagmus.

Primary outcome measure(s)

  • Visual field volume — Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.
    It will consist of the volume defined by two parallel surfaces bounded by the visual fields perceived with clear horizontal and vertical vision by the patient between the distances of 4 m and 25 cm while wearing each pair of spectacles. The volume will be calculated using the Heronian formula for the volume of a quadrangular pyramidal frustum.

Trial sites (1)

FacilityCityRegionStatus
Pharmacy school, University of Seville Seville Sevilla
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07617090 on ClinicalTrials.gov ↗ ← All trials in Spain